Biogen (BIIB) Net Cash Flow (2009 - 2026)

Biogen has reported Net Cash Flow for 18 years, with the latest figure at -$2.1 billion in Q2 2026.

• On a quarterly basis, Net Cash Flow fell 2371.48% year-over-year to -$2.1 billion in Q2 2026; TTM through Jun 2026 was -$1.5 billion, a 286.28% decrease from a year earlier, with the FY2025 full-year figure at $531.6 million, down 61.83% from the prior year.
• Net Cash Flow was -$2.1 billion for Q2 2026 at Biogen, down from $392.2 million in the prior quarter.
• The five-year high for Net Cash Flow was $1.1 billion in Q3 2025, with the low at -$2.1 billion in Q2 2026.
• Average Net Cash Flow over 5 years is -$53.8 million, with a median of -$102.2 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2026: Net Cash Flow soared 718.59% in 2022, then slumped 2371.48% in 2026.
• Over 5 years, Net Cash Flow stood at -$323.5 million in 2022, then sank by 297.5% to -$1.3 billion in 2023, then surged by 158.34% to $750.2 million in 2024, then tumbled by 214.21% to -$856.8 million in 2025, then slumped by 144.43% to -$2.1 billion in 2026.
• The last three Net Cash Flow figures came in at -$2.1 billion (Q2 2026), $392.2 million (Q1 2026), and -$856.8 million (Q4 2025), per Business Quant data.